Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study
Our study suggested that patients treated with obinutuzumab had a higher risk of prolonged SARS-CoV-2 infection and severe COVID-19 than those treated with rituximab.
Authors
- Jiaqi Tong
- Jing Le (ORCID: https://orcid.org/0000-0002-1473-756X)
- Wenxiu Shu
- Dian Jin (ORCID: https://orcid.org/0000-0002-0919-7239)
- Liufei Luo
- Yanping Song (ORCID: https://orcid.org/0000-0002-6961-994X)
- Qianqian Cai (ORCID: https://orcid.org/0000-0003-1661-7075)
- Qianqian Yang (ORCID: https://orcid.org/0000-0002-4331-5059)
- Hui Dai (ORCID: https://orcid.org/0000-0001-5024-559X)
- Dengbing Chen
- Bingrong Chen
Institutions
- Ningbo Medical Center Lihuili Hospital (CN)
Publication Details
- Journal
- Virology Journal
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1186/s12985-024-02484-x
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13